Tango Therapeutics TNGX Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's share-based payment award options outstanding - number?
- Tango Therapeutics (TNGX) reported share-based payment award options outstanding - number of 24.1M in Q1 2026.
- How has Tango Therapeutics's share-based payment award options outstanding - number changed year-over-year?
- Tango Therapeutics's share-based payment award options outstanding - number increased by 1.2% year-over-year, from 23.8M to 24.1M.
- What is the long-term trend for Tango Therapeutics's share-based payment award options outstanding - number?
- Over 4 years (2021 to 2025), Tango Therapeutics's share-based payment award options outstanding - number has grown at a 21.6% compound annual growth rate (CAGR), from 9.4M to 20.5M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.